Iyuzeh FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 27, 2022.
FDA Approved: Yes (First approved December 13, 2022)
Brand name: Iyuzeh
Generic name: latanoprost
Dosage form: Ophthalmic Solution
Company: Thea Pharma, Inc.
Treatment for: Intraocular Hypertension, Glaucoma, Open Angle
Iyuzeh (latanoprost) is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Latanoprost is an established treatment for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). It was first approved under the brand name Xalatan in 1996.
- Iyuzeh is the first and only preservative-free formulation of latanoprost.
- Iyuzeh is administered by instilling one drop into the affected eye(s) once daily in the evening.
- Warnings and precautions associated with Iyuzeh include pigmentation of the iris, periorbital tissue (eyelid) and eyelashes; and gradual changes to the eyelashes including increased length, thickness and number of lashes.
- Common adverse reactions include conjunctival hyperemia, eye irritation, eye pruritus, abnormal sensation in eye, foreign body sensation in eyes, vision blurred and increased lacrimation.
Development timeline for Iyuzeh
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
